See more : Andes Technology Corporation (6533.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Neoleukin Therapeutics, Inc. (NLTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neoleukin Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Genk Logistics Naamloze vennootschap (GENK.BR) Income Statement Analysis – Financial Results
- Nisshin Seifun Group Inc. (2002.T) Income Statement Analysis – Financial Results
- AUTOWAVE Co., Ltd. (2666.T) Income Statement Analysis – Financial Results
- Asian Alliance International Public Company Limited (AAI.BK) Income Statement Analysis – Financial Results
- Beneficient (BENFW) Income Statement Analysis – Financial Results
Neoleukin Therapeutics, Inc. (NLTX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.neoleukin.com
About Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 6.00K | 451.00K | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 6.00K | 451.00K | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 41.13M | 39.16M | 24.34M | 4.42M | 41.79M | 36.27M | 28.38M | 15.80M | 18.08M | 7.54M | 6.05M |
| General & Administrative | 17.97M | 21.54M | 17.21M | 18.83M | 15.84M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.97M | 21.54M | 17.21M | 18.83M | 15.84M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M |
| Other Expenses | -42.00K | 6.00K | -44.00K | -8.00K | -445.00K | -39.00K | -43.00K | -369.00K | -254.89K | 0.00 | 64.03K |
| Operating Expenses | 59.10M | 60.70M | 41.55M | 23.24M | 57.62M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M |
| Cost & Expenses | 59.10M | 60.70M | 41.55M | 23.24M | 57.62M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M |
| Interest Income | 1.58M | 19.00K | 490.00K | 1.54M | 1.56M | 998.00K | 619.00K | 0.00 | 0.00 | 26.32K | 0.00 |
| Interest Expense | 1.58M | 0.00 | 0.00 | 1.00K | 4.00K | 4.00K | 1.00K | 99.00K | 461.59K | 42.92K | 9.47K |
| Depreciation & Amortization | 2.61M | 2.28M | -13.84M | 49.59M | 1.04M | 940.00K | 644.00K | -421.00K | 135.95K | 59.57K | 130.78K |
| EBITDA | -56.49M | -60.70M | -47.56M | -21.37M | -31.51M | -50.16M | -37.07M | -21.71M | -24.38M | -9.68M | -7.53M |
| EBITDA Ratio | 0.00% | -1,011,633.33% | -10,546.34% | 0.00% | -126.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -59.10M | -60.70M | -33.73M | -70.96M | -32.62M | -51.12M | -37.65M | -21.34M | -23.57M | -9.38M | -7.66M |
| Operating Income Ratio | 0.00% | -1,011,633.33% | -7,478.49% | 0.00% | -130.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.54M | 6.00K | 7.83M | 1.52M | 1.04M | 936.00K | 643.00K | -520.00K | 487.60K | 641.24K | -9.47K |
| Income Before Tax | -57.56M | -60.69M | -33.28M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -24.03M | -8.73M | -7.67M |
| Income Before Tax Ratio | 0.00% | -1,011,533.33% | -7,378.49% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.54M | -2.28M | -8.32M | -7.00K | -1.04M | -940.00K | -644.00K | 421.00K | -222.00 | -5.04K | 42.29K |
| Net Income | -56.02M | -58.42M | -24.96M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -23.82M | -9.30M | -12.14M |
| Net Income Ratio | 0.00% | -973,583.33% | -5,533.48% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 | -2.08 |
| EPS Diluted | -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 | -2.08 |
| Weighted Avg Shares Out | 11.04M | 11.01M | 10.37M | 5.41M | 4.70M | 4.69M | 3.78M | 2.53M | 1.73M | 1.17M | 1.17M |
| Weighted Avg Shares Out (Dil) | 11.04M | 11.01M | 10.37M | 5.41M | 4.70M | 4.69M | 3.78M | 2.53M | 1.73M | 1.17M | 1.17M |
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a...
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a...
Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc
San Francisco-based investment firm, Redmile Group, LLC (Trades, Portfolio), recently increased its holdings in Neoleukin Therapeutics Inc ( NLTX , Financial), a biopharmaceutical company based in the USA. This article provides an in-depth analysis of the transaction, the profiles of...
NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Neoleukin Therapeutics, Inc. (NasdaqCM: NLTX) with Neurogene Inc. Under the terms...
Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene
MILWAUKEE , July 18, 2023 /PRNewswire/ -- Ademi LLP is investigating Neoleukin (Nasdaq: NLTX) for possible breaches of fiduciary duty and other violations of law in its private placement and its transaction with Neurogene. Click here to learn how to...
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) and Neurogene Inc. is fair to Neoleukin shareholders. Pre-merger Neoleukin stockholders are expected to own approximately 16% of the...
Neurogene and Neoleukin Announce Definitive Merger Agreement
NEW YORK and SEATTLE, July 18, 2023 (GLOBE NEWSWIRE) -- Neurogene Inc., a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, and Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) today announced that they have...
Neoleukin Therapeutics: Strategic Review Play
Neoleukin Therapeutics: Strategic Review Play
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan
Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce.
Shares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or merger
Neoleukin Therapeutics is slashing its workforce by about 70% as it seeks “strategic alternatives” for its future, according to a company statement Wednesday.
Source: https://incomestatements.info
Category: Stock Reports